67 results
Page 2 of 4
8-K
EX-10.1
jdg6l bhu
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
pbl657u oc
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
lx6fmsvw ay
8 May 23
Prospectus supplement for primary offering
5:18pm
10-K/A
1jqpqnvsf956z
28 Apr 23
Annual report (amended)
4:15pm
8-K
EX-99.1
fbquur
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
DEFA14A
6lv4tgge u7k3g
8 Dec 22
Additional proxy soliciting materials
8:31am
DEF 14A
r1fwoan977 1meu
25 Nov 22
Definitive proxy
6:16am
8-K
EX-1.1
sfgzwwz874i
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm
424B5
oi0wn4x 42
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
5fx3dc2 7yg
8 Nov 22
Quarterly report
4:09pm
8-K
EX-1.1
voltf3b3pk01td
21 Oct 22
Entry into a Material Definitive Agreement
4:19pm
424B5
z7h98meioi mwm
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
jixxsa7k bg6djul
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
8-K
91jq5lwkrvbwi
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
8-K
EX-5.1
e3keo7t hivuu6
13 Oct 22
Other Events
5:04pm
424B5
c4zgggrysx
13 Oct 22
Prospectus supplement for primary offering
4:56pm
S-8 POS
0puk9nmctnq
13 Oct 22
Registration of securities for employees (post-effective amendment)
4:46pm